DLAT and prostate adenocarcinoma: The results showed that, except for HCC, DLAT was expressed at higher levels in bile duct cancer, esophageal cancer, lung adenocarcinoma, lung squamous cell carcinoma, and gastric adenocarcinoma compared with normal tissue, while it was expressed at lower levels in invasive breast cancer, colon cancer, head and neck squamous cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, prostate adenocarcinoma, rectal adenocarcinoma, melanoma metastasis, and thyroid cancer.